Alnylam and CAMP4 partner to identify new targets to treat a rare liver disease

Liver
Alnylam and CAMP4 Therapeutics are partnering with a focus on identifying druggable targets for possible treatments of a rare liver disease. (Database Center for Life Science/CC BY-SA 2.1)

Alnylam Pharmaceuticals and CAMP4 Therapeutics, a bioinformatics startup, are partnering with a focus on identifying druggable targets for possible treatments of a rare disease of the liver.

The deal pairs Alnylam’s RNAi therapeutics expertise with CAMP4’s platform that decodes the physical structures used to unlock and turn on or off the expression of individual genes that can cause a disease.

Under terms of the deal, CAMP4 will get an undisclosed upfront payment from Alnylam, with additional milestone payments. CAMP4 could receive additional payments dependent on development, regulatory approval and sales milestones and well as royalties on products developed.

CONFERENCE

AI Innovations for Life Science and Healthcare Summit East

Join the expert speaking faculty of over 30 life science, healthcare, and tech professionals on June 13–14, 2019, in Philadelphia, as we elevate clinical trial operations, healthcare outcomes, and supply chain implementation through AI. Use Discount Code 796819FIERCE to save 15% off the standard registration rate.

“Our Gene Circuitry Platform is yielding the first-ever, comprehensive and dynamic understanding of the Cellular Operating System used by human liver cells to regulate the activation of genes and is applicable to any disease-associated genes in the liver,” Josh Mandel-Brehm, CAMP4’s chief executive, said in a statement. "We look forward to applying this knowledge to elucidate the optimal targets Alnylam can explore for potential RNAi intervention for a disease where there are currently no available treatment options.”

CAMP4, which was formed in 2016, reeled in $30 million in series A funding last year. In November, Vir Biotechnology announced it was initiating a phase 1/2 trial of its gene-silencing drug for hepatitis B, the first clinical candidate from its partnership with Alnylam.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.